Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


The Fertility Show


 

Growing sperm in the lab: an embryonic science

07 March 2016

By Dr Dusko Ilic

Appeared in BioNews 842

A recent press release from the Chinese Academy of Sciences announced the publication of research showing that scientists had created functioning spermatozoids from mouse embryonic stem cells in the laboratory (see BioNews 841). This made quite a splash in the media who suggested this new technology could allow infertile men to have children. I cannot blame the media; this is what both the press release and the actual article in Cell Stem Cell suggested (Zhou et al., 2016). However, one key point seemed to be overlooked – adult infertile men do not have embryonic stem cells; these cells exist only in embryos.

Apparently it must have been automatically assumed that the technology would work with iPSCs (induced pluripotent stem cells) too. But, although reprogramming technology has been advancing at tremendous speed, we cannot ignore that mutations in adult cells accumulate over the lifetime of the donor. And, the older a donor is, the higher the number of the mutations present.

A clinical trial in Japan, in which patients with age-related macular degeneration were treated with their own iPSC-derived retinal pigment epithelial cells, had to be halted because reprogrammed cells from one patient were found to contain a novel mutation that was not present in the original cells. Therefore, to assure success in creating sperm cells this way, we would have to generate and analyse multiple iPSC clones from several rounds of reprogramming using the cells from different biopsied sites in the donor.

The Japanese scientists are circumventing the problem by avoiding autologous transplantation. Instead they are making a bank of iPSC lines with the most common HLA types using cells from umbilical cord blood, which are as genetically naïve as cells can be. Such cells will be used as an allogeneic therapy. The Japanese strategy has been adapted worldwide and iPSC-based personalised treatments now look further away than they did a couple of years ago.

Another obstacle is that reprogramming involves erasing and remodelling epigenetic marks such as DNA methylation in adult somatic cells in order to bring them back to embryonic level. The remodelling of the epigenetic signature during reprogramming is never complete and there is a possibility that any un-erased methylation sites could be linked with susceptibility to diseases. For example, there is evidence of involvement of DNA methylation in the aetiology of autism and psychosis. Quality control would have to be quite strict and, although we have the technology in our hands, is fairly complex and too costly to be routine.

Furthermore, even if the previous two obstacles were not there, not all infertile men could benefit from this technology. The causes of male infertility are of either genetic or physical nature. If the cause is genetic, the chances that this technology could help are quite slim.

For example, abnormalities in the azoospermia factor (AZF) locus on the Y chromosome cause varying degrees of spermatogenic failure, which are unlikely to be fixed without additional genetic manipulation. A group from Stanford University in California derived iPSC from infertile men with deletions in the AZF regions, associated with production of few or no sperm but normal somatic development (Ramathal et al., 2014).

They transplanted iPSCs directly into murine seminiferous tubules. The testicular microenvironment induced differentiation of the iPSCs into germ cell-like cells, which were indistinguishable from fetal germ cells. But iPSCs with mutations in the AZF region generated significantly fewer germ cell-like cells and they had distinct defects in gene expression when compared with normal controls. Therefore, the 10-20 percent of infertile men carrying a deletion on the Y chromosome with no sperm in ejaculate would not be able to benefit from this technology. The mutations that prevented formation of sperm in their bodies would interfere with sperm production in vitro too.

Finally, the costs of iPSC-based personalised treatment would be reasonably steep and it is unlikely any health insurance company would cover it. Thus, if this ever came to fruition, the patient will have to pick up the tab and pay from his own pocket.

Keeping all these obstacles in mind, I do not see clinical applications coming any time soon, even though further development of technology for iPSC-derived gametes could benefit men with non-genetic causes of infertility, as well as same-sex couples. It could allow these people to have children that are genetically theirs, a truly exciting prospect. But, as it is, the report is a significant achievement and major step forward in understanding the molecular mechanisms governing gametogenesis, and nothing more.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

15 August 2016 - by Dr Peter D Sozou 
This book makes a startling prediction – within the next 20 to 40 years, most people with access to good healthcare will no longer have sex to conceive their children. Instead, parents will simply provide a few skin cells as the raw material for production of embryos...
03 May 2016 - by Ayala Ochert 
Spanish scientists say they have created rudimentary sperm-like cells from skin and bone marrow cells taken from adult males...

29 February 2016 - by Helen Robertson 
Scientists in China have used stem cells to create rudimentary sperm that successfully fertilised mouse eggs to produce healthy offspring...
09 November 2015 - by Isobel Steer 
Men previously considered sterile have successfully fathered children thanks to a newly improved technique called round spermatid injection (ROSI)...
26 October 2015 - by Dr Nicoletta Charolidi 
A stem-cell therapy in mice shows promise for reversing infertility in women who have received cancer treatment...
13 July 2015 - by Rhys Baker 
A test to diagnose male infertility that uses RNA as a biomarker has been developed by researchers in the USA...
18 May 2015 - by Lubna Ahmed 
A French company claims to have grown human sperm cells in a laboratory for the first time....

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Moving the Boundaries of Human Reproduction

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Jacques Cohen

Dr Anna Smajdor

Dr Andy Greenfield

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation